Merck and Co Inc (MRK)

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Merck to Hold Second-Quarter 2026 Sales and Earnings Conference Call Aug. 4

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, will hold its second-quarter 2026 sales and earnings conference call...

Merck Announces New Agreement with ADAP Crisis Task Force to Improve Access and Care for People Living with HIV

Agreement will help state ADAP programs provide access to IDVYNSO™ (doravirine/islatravir) for eligible individuals Merck (NYSE: MRK), known as...

Tech Rally and PCE Inflation Relief Lift Wall Street; Nasdaq Futures Surge as Micron Lead Market Rally

Dow Jones, S&P 500 and Nasdaq Futures are trading sharply higher this Thursday, fueled by a massive rally in the tech sector and investor...

FDA Approves KEYTRUDA® (pembrolizumab) and KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph), each with Trodelvy® (sacituzumab govitecan-hziy) as First-Line Treatment of PD-L1+ (CPS ≥10) Advanced Triple-Negative Breast Cancer (TNBC)

First approval of PD‑1 inhibitors in combination with a Trop-2-directed antibody-drug conjugate (ADC) in advanced TNBC, marking a potentially...

Form 11-K - Annual report of employee stock purchase, savings and similar plans

Form 11-K - Annual report of employee stock purchase, savings and similar plans

Form 11-K - Annual report of employee stock purchase, savings and similar plans

The Quest to Repair What Multiple Sclerosis Takes Away

The Quest to Repair What Multiple Sclerosis Takes AwayBioMedWire Editorial Coverage: Multiple sclerosis ("MS") gradually strips people of...

The Quest to Repair What Multiple Sclerosis Takes Away

AUSTIN, Texas, June 24, 2026 (GLOBE NEWSWIRE) -- BioMedWire Editorial Coverage: Multiple sclerosis (“MS”...

European Commission Approves KEYTRUDA® (pembrolizumab) Plus Padcev® (enfortumab vedotin-ejfv) as First PD-1 Inhibitor Plus Antibody-Drug Conjugate Regimen for Adults With Cisplatin-Ineligible Resectable Muscle-Invasive Bladder Cancer

Approval based on results from the Phase 3 KEYNOTE-905 trial in which perioperative KEYTRUDA plus Padcev reduced the risk of event-free survival...

Merck’s Tulisokibart Met Primary and Key Secondary Endpoints in the Phase 3 ATLAS-UC Induction-only Study in Patients With Moderately to Severely Active Ulcerative Colitis (UC)

Tulisokibart is the first anti-TL1A monoclonal antibody to demonstrate clinical remission at 12 weeks in moderately to severely active UC in a...